Compliance to annual diabetic eye examination remains poor: 48-66% nationally and 18% in inner cities (1, 2) . To improve noncompliance to diabetic eye examination in an inner-city county hospital population with an undersupplied eye clinic, the Wishard-Eskenazi Teleretinal Diabetic Retinopathy Screening (WETDRS) program was implemented in June 2009. Four Topcon digital retinal cameras were purchased by the health system for screening of only patients lacking a documented eye clinic visit within the past year at four primary care clinics. Captured images were remotely interpreted by eye physicians and electronically reported back to primary care clinics. To determine the cost of teleretinal screening for diabetic retinopathy (DR) through primary care, we conducted a retrospective review from program initiation through February 2013 (45-month time period). Institutional review board approval was obtained, and research adhered to tenets of the Declaration of Helsinki. Comparison was made between screening cost by WETDRS and by direct eye clinic visit without teleretinal imaging for same noncompliant patients.
There were a total of 1,793 screenings: 269 (15%) had DR in at least one eye; 360 (20%) had at least one unreadable image. For all calculations, reduction of eye clinic physician workload was the common goal. As a proxy for fiscal cost of teleretinal screening to health plan payers, we applied the 2013 Medicare physician reimbursement rates based on the Medicare Resource-Based Relative Value Scale (3). For the primary care clinic visit, a patient's service was considered to be evaluation and management (E/M) level 3 (code 99213). With enrollment into WETDRS, service was upgraded to E/M 4 (99214) along with fee for teleretinal imaging (Current Procedural Terminology [CPT] 92227). Per WETDRS protocol, only participants having DR or an unreadable image were referred to the eye clinic for a new patient comprehensive eye examination (CPT 92004).
WETDRS total screening cost reduction was $43,710 for eye physician services avoided, which was then applied as a proxy for gain from investment to the program's return on investment (ROI) of teleretinal screening. Cost of retinal cameras was considered as a proxy for cost of investment, accounting for the major equipment commitment of a program's implementation (4); each retinal camera cost $20,495. WETDRS generated an average cost reduction per screen of $24.38, giving a ROI of 20.47, meaning that 53% of the investment cost had been gained back by study end. Calculation of ROI did not account for teleretinal screening of all diabetic patients or camera downtime/ residual value (underestimation) and additional hardware and staff costs (overestimation). Physician reimbursement rates and cost-analysis formulas and calculations are presented in Table 1 .
As defined by our cost-analysis formulas, teleretinal screening for DR at the primary care level generated screening cost reduction to health plan payers and ameliorated eye clinic physician workload but failed to break even on investment cost by study end. To be fiscally feasible in the county health system, our retrospective study suggests that strategic workflow planning before implementation of program (with decision on selection of screened patients, full utilization of cameras, time period for achieving break-even point) is critical for success. Cost per screening (CS) for a new patient comprehensive eye examination (CPT 92004). N referred, number of screens referred to eye clinic for DR or unreadable image. †Wishard Advantage (county health system-provided health plan) physician reimbursement rates were comparable to and applied at the Medicare rates. ‡Private health plan, self-pay, and missing data physician reimbursement rates were applied at the Medicare rates. A total of 110 (6%) screens were covered by private health plans; 94 (5%) were self-pay and 89 (5%) had missing data.
